Abbreviations used
BMI: Body mass index ICS: Inhaled corticosteroid SES: Socioeconomic status VIDA: Vitamin D Add-On Therapy Enhances Corticosteroid Responsiveness in Asthma VIF: Variance inflation factor health disparities, [2] [3] [4] [5] [6] including greater asthma morbidity. [7] [8] [9] [10] [11] [12] [13] [14] The mechanism for the association between lower SES and greater asthma morbidity is unclear, but several underlying factors have been hypothesized to causally link them. 3, [15] [16] [17] One such factor is vitamin D insufficiency, which has been associated with both greater asthma morbidity [16] [17] [18] [19] and lower SES. 20, 21 Another is the lower access and adherence to asthma controller therapy related to lower SES. [22] [23] [24] [25] [26] The National Heart, Lung, and Blood Institute-sponsored Vitamin D Add-On Therapy Enhances Corticosteroid Responsiveness in Asthma (VIDA) trial examined whether vitamin D supplementation could improve asthma control when added to inhaled corticosteroid (ICS) therapy in participants with low serum vitamin D levels. 27 Although vitamin D supplementation did not significantly reduce treatment failures compared with placebo overall, it did so in the subgroup who achieved vitamin D sufficiency with supplementation. We collected detailed information on 3 SES correlates-income, education, and perceived stress-in the setting of reliable and equal access to controller asthma therapy and monitored adherence. We hypothesized that low SES would be associated with poor asthma outcomes because of lower vitamin D levels at baseline, an inability to achieve vitamin D sufficiency with supplementation, or a differential effectiveness of vitamin D supplementation.
METHODS
A detailed description of the recruitment, design, study visit structure, and procedures, including spirometry and statistical analysis, for the VIDA trial has been reported previously. 27 
Participants
We conducted a secondary analysis of a multicenter, randomized, doubleblind, placebo-controlled trial (VIDA). Eligible participants were aged greater than 18 years with asthma confirmed by b-agonist reversibility or methacholine responsiveness. Participants were vitamin D insufficient (baseline serum 25-[OH]D 3 level, <30 ng/mL), had uncontrolled symptoms despite low dose-ICS therapy, and had predicted FEV 1 of greater than 50%. Four hundred eight participants were randomized to placebo or cholecalciferol for 28 weeks as add-on therapy in the setting of a tapering ICS regimen. Participants were recruited from 16 academic US medical centers and excluded if they did not meet entry or run-in criteria. 27 
Procedures and outcomes
The study protocol was approved by the institutional review board at each participating institution. 27 The a priori primary outcome was treatment failure, which was defined as more than 1 of the following: peak expiratory flow of less than 65% of baseline (2 of 3 consecutive measurements), FEV 1 of less than 80% of baseline (2 consecutive measurements), levalbuterol dose increase by greater than 8 puffs/d for 48 hours (vs baseline), additional ICS or systemic corticosteroid treatment, asthma-related emergency department visit or hospitalization with systemic corticosteroid treatment, participant's dissatisfaction with treatment, and physician's clinical safety judgment. The secondary outcome was asthma exacerbation, which was defined as meeting treatment failure criteria and more than 1 of the following: failure to respond to rescue algorithm within 48 hours, FEV 1 of less than 50% of baseline or less than 40% of predicted (2 consecutive measurements), levalbuterol use of more than 16 puffs/d for 48 hours, exacerbation per physician's opinion, and systemic corticosteroid treatment for asthma.
SES data were collected from questionnaires standardized across study sites and administered by centrally trained clinical staff. Race, ethnicity, and household size were self-reported. Combined household annual income level was collected as follows: less than $25,000, $25,000 to $49,999, $50,000 to $99,999, or greater than $100,000 and defined as low if less than $50,000. [28] [29] [30] Highest household education level was collected as no high school diploma, GED, high school diploma, technical training, some college but no degree, Associate's degree, Bachelor's degree, Master's degree, or MD/PhD/JD/PharmD and defined as low if less than a Bachelor's degree. 31, 32 Perceived stress was measured by using the Perceived Stress Scale and defined as high if the Perceived Stress Scale score was 20 or greater. [33] [34] [35] Adherence to study drug was measured as follows: ciclesonide was monitored with the MediTrack DOSER device, vitamin D and placebo capsules were monitored with the Aardex MEMS 6 cap, and oral corticosteroids were measured with a pill count. Study drugs were supplied free of charge to subjects. Sensitization to aeroallergens was determined by means of skin prick tests with standard allergen preparations from Greer Laboratories (Lenoir, NC).
Statistical methods
Comparisons were made between the placebo and vitamin D treatment groups for categorical variables, such as race and income, by using Pearson x 2 or Fisher exact tests, and continuous or ordinal variables, such as age and vitamin D levels, by using 2-sample t tests or Wilcoxon rank sum tests, as appropriate. Poisson regression models were chosen to model the number of treatment failures and exacerbations as appropriate for modeling count data while considering the duration of follow-up for each participant included as the offset on the natural log scale. 36, 37 A log-linear relationship was assumed between the mean number of events and the factors included in the model. Overdispersion of each model was assessed by evaluating the deviance statistic and ensuring that the deviance/DF value was close to 1. These models were first evaluated individually to determine the effect of each SES factor on individual event outcomes adjusting for study site, race (black vs nonblack), body mass index (BMI; < _25 vs >25 kg/m 2 ), and treatment (vitamin D vs placebo) per the primary VIDA trial analysis as follows:
where Y i is the number of events, t i is the length of time in the study, x i is the vector of covariates included in the model, and b is the vector of regression parameters. Subsequently, additional Poisson models evaluated the effects of all 3 SES correlates simultaneously, adjusting for the above plus additional relevant covariates (age, sex, ethnicity, BMI, household size and education, perceived stress, baseline FEV 1 percent predicted, bronchodilator response, hospitalization rate, and secondhand smoke exposure). Collinearity among the covariates was evaluated by using the variance inflation factor (VIF), 38 and only covariates with a VIF of less than 10 were included in the models. 39 Interaction terms between SES correlates and treatment assignment and between SES correlates and race were created to determine whether vitamin D treatment and race modified associations with asthma outcomes. Results for individual predictors are presented in terms of Wald x 2 statistics and P values from the Poisson regression models, as well as rate ratios and 95% CIs to compare event rates between groups. A sample size of 408 participants was determined based on the primary hypothesis of the main clinical trial. All analyses were performed with SAS 9.4 software (SAS Institute, Cary, NC).
RESULTS
We collected information on 381 (93.4%) of the 408 participants in the VIDA trial who contributed information on income, J ALLERGY CLIN IMMUNOL VOLUME 141, NUMBER 2 as well as education or stress. Table I describes the baseline characteristics of these subjects stratified by treatment assignment. Mean age was 40 years, with the majority composed of female and white subjects. Most participants were overweight or obese. Per the inclusion criteria, all participants had mild-to-moderate asthma and were maintained on more than 1 asthma controller medication before enrollment. Fifty-four percent of participants had a household income of less than $50,000, 40% had a household educational level of less than a Bachelor's degree, and 17% reported high stress levels. Table II demonstrates the relationships between SES correlates and asthma outcomes tested individually in separate Poisson regression models. Only a household income of less than $50,000 was significantly associated with poor asthma outcomes (P 5 .01 for both treatment failures and exacerbations). The rate of treatment failures was 1.6-fold (95% CI, 1.1-2.3) higher, and the rate of exacerbations was 2.0-fold (95% CI, 1.2-3.3) higher in participants with a household income of less than $50,000 compared with those with higher income. In contrast, neither household educational level nor perceived stress were associated with treatment failures (P 5 .06 and P 5 .39) or exacerbations (P 5 .34 and P 5 .54), respectively.
Because of the link between race, ethnicity, and other SES correlates, we also tested the relationship between race and ethnicity and asthma outcomes in individual models (Table II) . Of these demographic characteristics, only race was significantly associated with poor asthma outcomes (P 5 .001 for treatment failures and P 5.03 for exacerbations). The rate of both treatment failures (95% CI, 1.2-2.4) and exacerbations (95% CI, 1.0-2.6) in black subjects was 1.7-fold higher than in nonblack subjects.
Hispanic/Latino ethnicity was not significantly associated with treatment failures (P 5 .09) or exacerbations (P 5 .23; rate ratio, 0.6 for both). Black subjects were more likely to have an income of less than $50,000 (74% of black vs 45% of nonblack subjects, P < .0001). We tested whether race and other relevant covariates confounded the associations between household income and asthma outcomes; these covariates did not weaken the association between household income and asthma outcomes (see Table E1 in this article's Online Repository at www.jacionline.org for 7 models analyzing this association). These relevant covariates were evaluated for collinearity before inclusion in the models (all VIFs between 1.0 and 1.3).
In our final multivariate model participants with low income experienced a 1.5-fold (95% CI, 1.0-2.2; P 5 .034) higher rate of treatment failures per person-year than those with high income, with adjustment for study site, race, BMI, and treatment (Table  III) . Similarly, those with low income experienced a 1.8-fold (95% CI, 1.1-3.1; P 5 .025) greater rate of exacerbations per person-year than those with high income (Table III) . We retested this model using a 4-category definition of income (<$25,000, $25,000-$49,999, $50,000-$99,999, and >$100,000) to examine whether the association was ordinal. We found that lower income levels associated with progressively poorer asthma outcomes, but the income groups did not demonstrate a statistically significant ordinal association (P 5 .07 for both treatment failures and exacerbations) with adjustment for study site, race, BMI, and treatment.
To further address whether the effect of household income on asthma outcomes is independent of race, we stratified our analyses by race. For both black and nonblack subgroups, participants with low income had poorer asthma outcomes compared with those with high income, but this was not statistically significant. This test of race by income interaction was not statistically significant for either treatment failures (interaction P 5.72) or exacerbations (interaction P 5.99, see Table E2 in this article's Online Repository at www.jacionline.org), suggesting that race does not potentiate the relationship between income and asthma outcomes. Adherence to ICS therapy and dose of ICS therapy were not statistically significantly different between income groups. Lowincome participants were adherent 94.85% of days, and highincome participants were adherent 94.15% of days (P 5 .23). Similarly, low-income participants used a median of 2.57 ICS puffs per day, whereas those with high income used a median of 2.58 puffs per day (P 5 .27).
Subjects with low incomes were more likely to be female (P <.01) and black (P <.01) and have higher BMI (P <.01), higher perceived stress levels (P 5.04), and lower household educational levels (P < .0001) compared with those with higher income. Participants with lower incomes also had a lower baseline Asthma Control Test score (18.8 vs 19.5, P 5 .03) and a greater bronchodilator response compared with the higher income group (percentage change in FEV 1 , 15.5% vs 13.2%; P 5 .03). Participants with low incomes were more likely to be hospitalized for asthma exacerbations (7.2% vs 2.3%, P 5 .03). Both income groups were similar in terms of other covariates (see Table E3 in this article's Online Repository at www.jacionline.org).
Having identified low income as an independent risk factor for worse asthma outcomes, we addressed whether this risk was mediated by issues related to vitamin D insufficiency (eg, baseline levels, ability to achieve sufficiency, and response to treatment). Participants with low income had a mean vitamin D level of 18.2 ng/mL, whereas those with a high income had a mean vitamin D level of 19.4 ng/mL (P 5 .09).
Because black subjects were overrepresented in the lowincome group (black subjects represent 44% of the low-income and 18% of the high-income subgroup, P <.01) and black subjects had lower baseline vitamin D levels (15.6 vs 20.3 ng/mL, P < .001), we compared baseline vitamin D levels between nonblack subjects across income categories. The nonblack lowincome subgroup had a baseline vitamin D level of 20.2 ng/mL, whereas the high-income subgroup had a level of 20.3 ng/mL, which was not statistically different (P 5 .93). Supplementation resulted in vitamin D sufficiency in 82% of participants in VIDA, and low income was not a predictor for achieving vitamin D sufficiency (P 5 .84).
Lastly, we considered whether treatment with vitamin D was differentially effective in the low-income subgroup. The low-income subgroup had poorer asthma outcomes than the highincome subgroup independent of treatment assignment (Figs 1 and 2 and Table IV); however, this was not statistically significant. The test for effect modification by treatment assignment on the relationship between income and asthma outcomes was not statistically significant for either treatment failures (interaction P 5.83) or exacerbations (interaction P 5.59, Table IV), suggesting that vitamin D supplementation does not attenuate the relationship between income and asthma outcomes.
DISCUSSION
In this randomized controlled trial of adults with mild-tomoderate asthma, we identified income as an independent risk factor for poor asthma outcomes. The treatment failure rate in participants with a household income of less than $50,000 was 1.5-fold higher and the exacerbation rate was 1.8-fold higher compared with participants with a household income of greater than $50,000. These results were robust to adjustment by age, sex, race, BMI, study site, treatment, ethnicity, household size and education, perceived stress, baseline lung function and hospitalization rate, and secondhand smoke exposure.
Income as an independent risk factor for asthma morbidity has been well described in the asthma disparities literature. 9, 14, 40 A significant limitation of these studies is that many important patient characteristics and asthma-related outcomes (eg, access or adherence to asthma controller therapy, asthma severity, and asthma exacerbations) are ascertained through self-report. Our study is novel in that our data derive from a randomized controlled trial, with extensive, centrally regulated clinical characterization and longitudinal follow-up. In this trial participants were provided with and were highly adherent to ICS therapy, with similar amounts of ICS use across income categories. In this trial participants were provided with and were highly adherent to ICS therapy, with similar amounts of ICS across income categories. Thus our finding challenges the commonly posited hypothesis that greater morbidity is seen in low-income patients with asthma, solely because of lack of access or adherence to ICS, although these findings need to be confirmed in a real-world setting. [22] [23] [24] [25] [26] We hypothesize that there are additional unknown factors contributing to low income being associated asthma morbidity. Secondhand smoke is unlikely to explain the income-asthma outcome association because only a minority of participants reported exposure to it (<10% for both income categories); our results were also robust to adjustment by secondhand smoke exposure. Another commonly held notion is that cockroach and dust mite sensitization can be related to exposure in some inner-city asthmatic populations. 41 These allergens are thought to be important in the J ALLERGY CLIN IMMUNOL VOLUME 141, NUMBER 2 genesis or maintenance of asthma and possible drivers of worse outcomes. [42] [43] [44] Surprisingly, our results show similar sensitization patterns to perennial aeroallergens across income categories (see Table E3 ). This might be due to our study population being composed only of participants aged greater than 18 years and not a pediatric population, which might be more susceptible to the proasthmatic effects of exposure and sensitization to perennial aeroallergens.
The proasthmatic factor associated with low income remains unclear from our results. We hypothesized that this proasthmatic factor in low-SES participants would relate to vitamin D insufficiency, given its association with both asthma and lower SES. However, our results suggest the contrary because participants had comparable baseline vitamin D levels and similarly achieved vitamin D sufficiency with supplementation across income categories. Furthermore, treatment with vitamin D did not modify the association between income and asthma outcomes.
The low-income subgroup had a significantly greater reversibility with albuterol (15.5% vs 13.2% increase in FEV 1 , P 5 .03) and a higher frequency of asthma-related hospitalizations in the year before enrollment (7.2% vs 2.3%; P 5 .03), suggesting that the low-income subgroup might have had worse disease at enrollment (see Table E3 ). Nonetheless, clinical and spirometric differences are unlikely to explain our results because their inclusion into our models did not weaken the income-asthma outcome association (see Table E1 ).
The correlation between SES factors and race is frequently raised as a limitation in disparities studies because of historical issues in the United States regarding residential segregation. 32 However, our results suggest that income is an independent risk factor for adverse asthma outcomes irrespective of race. We tested for interactions between these 2 characteristics and found that race did not modify the income-adverse asthma outcome association. A limited sample size might explain this test's lack of statistical significance, but participants with low incomes had higher rates of adverse asthma outcomes regardless of race, which supports our results. We were similarly limited and underpowered to test for effect modification by treatment on the income-adverse asthma outcomes association. Again, participants with low incomes had higher rates of adverse asthma outcomes regardless of treatment assignment.
Another limitation was our categorical definition for household income with setting a threshold at $50,000/y. The distribution of the household income categorical variable had the most powerful balanced comparison between those with incomes of less than $50,000 versus those with incomes of $50,000 or greater. Additionally, this cutoff has been used in the disparities literature because it is the lowest income sufficient to cover the basic needs of an average family. [28] [29] [30] Furthermore, although we did not use federal poverty levels to define income in our models, we approximated these levels by adjusting by household size, which affects federal poverty levels. We evaluated whether an ordinal association existed between income and asthma outcomes when applying a 4-category income definition (<$25,000, $25,000-$49,999, $50,000-$99,999, and >$100,000) because of the imbalance in the sample size for these categories. Although these tests suggested an ordinal relationship between income and asthma outcomes, limited sample sizes likely explain their lack of statistical significance (P 5 .07 for both outcomes).
Another limitation of this analysis is the fact that the sample size for the clinical trial was determined by the primary research hypothesis and not by the measures included in the secondary analysis. Moreover, because this analysis was conducted on clinical trial participants, there is limited generalizability because subjects were closely monitored in regard to medication use, were given free medications, had regular study visits, and had low vitamin D levels. Finally, we did not find household education or perceived stress to be associated with asthma outcomes. We caution against concluding that these 2 SES correlates are unrelated to asthma outcomes; these negative findings might be specific to our cohort or ascertainment methods.
In summary, we found that in the setting of a randomized clinical trial, lower household income is associated with poor asthma outcomes. The factors underlying lower income as a risk factor for worse asthma are unknown and warrant further research. Clinicians should be aware of the higher morbidity associated with low income for reasons independent of asthma severity, lung function, and access and compliance with controller therapy. Clinical researchers might want to ensure that randomization of trial participants account for household income to adequately balance risk factors.
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Key messages
d Observational studies have limitations in their ability to examine disparities in asthmatic patients because these studies have relied on self-reported measures of medication use, asthma diagnosis, severity, outcome, and access to care.
d Using data collected from a randomized controlled trial, we found that subjects with lower income had a significantly higher number of asthma treatment failures and asthma exacerbations independent of race, BMI, education, perceived stress, baseline lung function, hospitalization, ICS adherence, ICS dose, environmental allergen sensitization, and secondhand smoke exposure. 
